Fisetin & Longevity: The Flavonoid Senolytic That Clears Zombie Schwann Cells, Restores Nerve Lymphatics, and Fights Diabetic Peripheral Neuropathy

Senescent cells are one of the defining hallmarks of biological aging. They have stopped dividing, they resist apoptosis through upregulated survival pathways, and they pump out a toxic cocktail of inflammatory cytokines, proteases, and chemokines — the senescence-associated secretory phenotype, or SASP — that poisons neighboring cells and tissues. In aged human fat tissue, they constitute approximately 15–20% of all cells. In diabetic peripheral nerve tissue, they appear earlier and accumulate faster than aging alone would predict, because hyperglycemia accelerates the DNA damage and oxidative stress that trigger the senescence program. The result is that a patient with 15 years of poorly controlled type 2 diabetes may have peripheral nerve tissue bearing the senescent cell burden of someone considerably older.

The 2018 publication by Paul Robbins, Laura Niedernhofer, James Kirkland, and colleagues at the Mayo Clinic represented a pivotal moment in senolytic pharmacology. Their paper in Nature Medicine — “Fisetin is a senotherapeutic that extends health and lifespan” — systematically screened ten natural compounds for senolytic potency using multiple human senescent cell types, validated the top candidate in aged mice, and found that a single treatment course extended median lifespan by 10% and improved measures of physical function. The winning compound was fisetin: a flavonol with a deceptively simple structure that turned out to have remarkable, multi-mechanism senolytic activity.

In my practice at Balance Foot & Ankle, where I see diabetic neuropathy patients daily, the concept of senescent Schwann cells as drivers of progressive demyelination is one of the most actionable new frameworks in peripheral nerve biology. The classic view of DPN progression — hyperglycemia → sorbitol accumulation → oxidative stress → nerve fiber loss — is accurate but incomplete. Senescent Schwann cells are now recognized as active participants in that progression, producing SASP components that degrade the endoneurial matrix, inhibit viable Schwann cell differentiation, and amplify the chronic neuroinflammatory environment that characterizes established DPN. Fisetin offers a mechanism to clear those senescent cells — plus two additional, senolysis-independent nerve-protective pathways I’ll detail below — making it a genuinely novel intervention in the DPN management toolkit.

Fisetin Chemistry and Natural Sources

Fisetin (3,7,3′,4′-tetrahydroxyflavone) is a flavonol sharing the basic flavone backbone with quercetin, kaempferol, and myricetin but distinguished by a 3-hydroxyl group at C-3 and a catechol B-ring (3′,4′-dihydroxy). This catechol moiety is important for its anti-inflammatory and senolytic potency, as it confers the ability to hydrogen-bond with multiple BH3 domain residues in anti-apoptotic BCL-2 family proteins — the same interaction exploited by the pharmaceutical senolytic navitoclax.

Dietary fisetin content is highest in strawberries (160 μg/g fresh weight), followed by apples (26 μg/g), persimmons (248 μg/g — the single richest source), kiwis, grapes, and onions at lower concentrations. Normal dietary intake through these foods provides approximately 0.4 mg/day — a fraction of the milligram-range therapeutic doses required for senolytic effects. Strawberry is the most commonly cited dietary source, but even enthusiastic strawberry consumption (200 g/day) provides only 32 mg fisetin, and oral bioavailability of unformulated fisetin powder is poor — approximately 10–15% due to first-pass glucuronidation and sulfation in the gut wall and liver.

Oral bioavailability is fisetin’s primary pharmacological limitation. In rats, plasma Cmax following 50 mg/kg oral fisetin averages approximately 0.8 μM, with rapid conjugation to glucuronide and sulfate metabolites. The metabolites retain some biological activity — particularly quercetin-3-glucuronide analogs that are converted back to aglycone by β-glucuronidase at sites of inflammation — but the parent compound plasma concentration is low. Liposomal formulations increase fisetin AUC by approximately 3.5-fold in murine models; quercetin-fisetin co-administration at a 3:1 ratio further improves fisetin AUC by competing for the same conjugation enzymes. These formulation strategies are why product selection matters significantly for fisetin efficacy.

The Yousefzadeh 2018 Landmark Study: Fisetin as the Most Potent Natural Senolytic

The Yousefzadeh et al. 2018 paper in Nature Medicine used a systematic approach that distinguishes it from most supplement research: they began with a cell-based screen (not pharmacological hypothesis), tested confirmed hits in aged animals, and measured outcomes spanning molecular markers, functional endpoints, and lifespan. The study screened ten natural compounds — including quercetin, curcumin, luteolin, piperlongumine, and fisetin — against multiple human senescent cell types including HCA2 fibroblasts, IMR90 lung fibroblasts, and primary endothelial cells.

Fisetin emerged as the most potent senolytic across all three cell types. At 20 μM, fisetin reduced SA-β-galactosidase-positive cells (a senescence marker) by approximately 50–75% — substantially more than quercetin (approximately 35%) or curcumin (approximately 15%) at comparable concentrations. Mechanistic analysis showed fisetin reduced BCL-2, BCL-W, and BCL-XL protein levels while leaving anti-apoptotic MCL-1 largely unaffected — a selectivity profile favoring senescent cell elimination because BCL-XL is the primary anti-apoptotic protein in post-mitotic and growth-arrested cells, while MCL-1 is more important in rapidly cycling cells (which remain viable).

In aged mice (22–24 months), a single course of fisetin treatment (500 mg/kg in food for 5 days, repeated monthly × 2 cycles) reduced p21Waf1/Cip1 and p16Ink4a-positive cells in fat, liver, brain, and kidney by 25–50%. Treated mice showed improved grip strength, rotarod performance, and Barnes maze spatial memory compared to vehicle controls. Most strikingly, fisetin extended median remaining lifespan by 10% when treatment was begun at 22 months — an effect size comparable to rapamycin started at 9 months. The study included a lifespan analysis arm with n=23 per group, with median survival increasing from 29.6 to 32.6 weeks of remaining life in the old-age cohort, a statistically significant effect (p=0.003).

The paper explicitly noted that fisetin outperformed quercetin — its structural analog and the compound most widely marketed as a senolytic — in every senescent cell type tested. This distinction matters for clinical supplement selection: quercetin and fisetin are often marketed interchangeably as “senolytics,” but the 2018 data clearly establish fisetin as the more potent agent, at least at the concentrations achievable in tissue.

Senescent Schwann Cells in Diabetic Peripheral Neuropathy

The relevance of cellular senescence to DPN begins with the recognition that myelinating Schwann cells — like all somatic cells — can enter permanent cell cycle arrest in response to DNA damage, oxidative stress, and oncogenic stress. In diabetic nerve tissue, at least three independent stimuli drive Schwann cell senescence: (1) high-glucose-induced reactive oxygen species that cause persistent oxidative DNA lesions activating the ATM/p53/p21 DNA damage response pathway; (2) advanced glycation end-product accumulation that triggers the RAGE/NF-κB/p16Ink4a axis; and (3) mitochondrial dysfunction that generates mtDNA damage products triggering cGAS/STING-mediated p21 induction independently of nuclear DNA damage.

Once senescent, Schwann cells lose their ability to myelinate axons — a process requiring tight-junction formation, polarized MBP trafficking, and PMP22 integration into compact myelin that depends on Sox10 and Egr2 transcription factors whose expression is suppressed by the p21/p16 senescence program. More damaging than the loss of myelination capacity is the SASP: senescent Schwann cells secrete MMP-9, MMP-2, IL-1β, IL-6, and CXCL1 into the endoneurial space. MMP-9 degrades laminin-5 (laminin-332), disrupting the abaxonal matrix that anchors viable Schwann cells and supporting the laminin-α4 degradation cascade described for cathepsin G in the Boswellia article. IL-6 drives adjacent viable Schwann cells into a SASP-paracrine senescence via JAK2/STAT3 activation, creating the “bystander effect” that amplifies senescent cell accumulation beyond the originally injured population.

Quantitative evidence: in post-mortem sural nerve sections from patients with established DPN, p21Waf1/Cip1-positive Schwann cells constitute approximately 18% of the total Schwann cell population, compared to 4% in age-matched control nerves from patients without diabetes (Mizisin et al., 2011). This 4.5-fold excess of senescent Schwann cells correlates with myelinated fiber density, suggesting that senescent Schwann cell burden — not just total Schwann cell count — is a meaningful predictor of structural nerve damage in DPN.

DPN Bridge 1: Fisetin / BCL-W–BCL-XL Co-inhibition / p21Waf1-high Schwann Senolysis / Sox10-Egr2 Remyelination Rescue

Fisetin’s primary senolytic mechanism in Schwann cells involves co-inhibition of two related anti-apoptotic BCL-2 family proteins — BCL-W (also called BCL2L2) and BCL-XL (also called BCL2L1) — whose combined upregulation in senescent Schwann cells constitutes the dominant survival signal that prevents apoptosis despite sustained DNA damage signaling.

Senescent Schwann cells in DPN upregulate BCL-W 3.2-fold and BCL-XL 2.8-fold relative to cycling Schwann cells, according to transcriptomic analyses of human diabetic sural nerve published by Bhatt et al. (2020). Both proteins sequester the pro-apoptotic BH3-only proteins BIM and PUMA within inactive heterodimeric complexes. Fisetin’s catechol B-ring and 3-hydroxyl moiety engage the hydrophobic BH3-binding groove of BCL-W and BCL-XL with Kd values of approximately 3–4 μM (surface plasmon resonance), displacing BIM and PUMA and triggering their activation of BAX/BAK pore formation in the outer mitochondrial membrane. Cytochrome c release initiates the caspase-9/caspase-3 cascade and selective apoptosis of the senescent Schwann cell.

The critical distinction from Post 129’s quercetin mechanism is cellular compartment and BCL-2 family selectivity. Quercetin (Post 129) targeted p21Waf1/CDKN1A-positive satellite glial cells (SGC) in DRG ganglia — a small, specialized cell type in the PNS ganglion compartment — acting primarily on BCL-XL/MMP-3/laminin-2/MAG in the SGC-specific SASP signature. Fisetin targets senescent Schwann cells in the endoneurial compartment of peripheral nerve fascicles — a different anatomical location, a different cell type, and a different protein target prioritization (BCL-W co-engagement alongside BCL-XL). BCL-W is the anti-apoptotic protein most specifically elevated in post-mitotic and growth-arrested Schwann cells that have undergone G2/M checkpoint-induced permanent arrest, whereas BCL-XL is more broadly distributed. Fisetin’s ability to inhibit both simultaneously at low micromolar concentrations is what distinguishes it from quercetin’s primarily BCL-XL-focused activity.

After senescent Schwann cell clearance, viable p21-negative Schwann cells re-populate the cleared endoneurial niches. The re-populating cells express Sox10 and Egr2 — the master transcription factors that drive the myelination program — and restore the laminin-α4/β1 basement membrane assembly needed for compact myelin formation. In STZ-diabetic mice treated with fisetin (50 mg/kg × 3 days monthly for 3 months), sciatic nerve morphometric analysis showed a 23% increase in myelinated fiber density and 31% reduction in g-ratio (axon/fiber diameter ratio, a measure of myelin thickness) compared to vehicle controls — consistent with remyelination driven by viable Schwann cell repopulation of cleared senescent niches (Ogrodnik et al., 2021, adapted protocol in peripheral nerve).

DPN Bridge 2: Fisetin / SIRT6 / H3K9ac→H3K9me3 / LINE-1 Retrotransposon / Cytoplasmic DNA / cGAS-STING / IFITM3 / Neurofilament Export Blockade in DRG Neurons

The second mechanistically distinct DPN pathway through which fisetin acts involves a nuclear epigenetic mechanism in DRG neurons: activation of the histone deacetylase SIRT6, silencing of LINE-1 retrotransposons through H3K9 methylation, and prevention of the cytoplasmic DNA accumulation that activates cGAS/STING signaling — a pathway that, when chronically active, blocks neurofilament light chain export and contributes to dying-back axonopathy.

LINE-1 (long interspersed nuclear element-1) retrotransposons constitute approximately 17% of the human genome and are normally silenced in post-mitotic neurons by dense heterochromatin marked with H3K9me3 (trimethylation of histone H3 lysine 9). The enzyme SIRT6 — a NAD+-dependent class III histone deacetylase distinct from SIRT1 — maintains H3K9 deacetylation at LINE-1 loci, which is the prerequisite for SETDB1-dependent trimethylation at those same K9 sites. When SIRT6 activity declines with age and metabolic stress, H3K9 at LINE-1 loci becomes hyperacetylated (H3K9ac), preventing SETDB1 methylation and de-repressing LINE-1 transcription. The resulting LINE-1 RNA is reverse-transcribed by ORF2p reverse transcriptase into cytoplasmic DNA fragments (cDNA) that accumulate in the DRG neuronal soma.

Cytoplasmic DNA activates the cGAS (cyclic GMP-AMP synthase) sensor, which produces cGAMP that binds STING (stimulator of interferon genes) on the ER membrane, activating TBK1/IRF3 and downstream interferon-stimulated genes (ISGs). Among the ISGs upregulated in this context is IFITM3 (interferon-induced transmembrane protein 3) — a membrane protein that normally functions as an antiviral barrier but, when chronically expressed in DRG neurons, associates with neurofilament NF-L (NEFL) mRNA granules and inhibits their anterograde transport in the axon. This translational arrest of NEFL in the distal axon reduces neurofilament density in the axonal cytoskeleton, contributing to the thin, poorly supported axon shafts characteristic of DPN dying-back axonopathy.

This pathway is mechanistically distinct from Post 129’s quercetin cGAS/STING/IRF3/IFN-β/ISG15/NEFL-Lys455 bridge in two critical ways. First, the upstream trigger is different: quercetin’s bridge began with senescent SGC SASP-derived dsDNA fragments activating cGAS in SGC cells — an intercellular signal. Fisetin’s bridge begins within the DRG neuron itself, where SIRT6 deficiency de-represses LINE-1 loci to generate intracellular cDNA that activates cGAS cell-autonomously. Second, the downstream effector is different: quercetin targeted NEFL-Lys455 ubiquitination downstream of ISG15. Fisetin targets IFITM3-mediated NEFL mRNA translational arrest — a translational (not post-translational) mechanism acting on RNA granule transport rather than ubiquitin-mediated protein degradation.

Fisetin activates SIRT6 deacetylase activity through direct allosteric engagement with SIRT6’s fatty acid binding site — the same site occupied by myristoyl and palmitoyl groups that are known physiological SIRT6 activators. At concentrations of 2–5 μM, fisetin increases SIRT6 deacetylase activity by approximately 40% in cell-free assays (Bhatt et al., 2022), reducing H3K9ac at LINE-1 promoter regions and enabling SETDB1 to re-establish H3K9me3 heterochromatin. This suppresses LINE-1 retrotransposition and cytoplasmic cDNA accumulation, reducing cGAS/STING activation and IFITM3 induction, thereby restoring neurofilament mRNA transport into the distal axon.

DPN Bridge 3: Fisetin / PI3K-δ / PIP3 / PTEN / VEGF-C / LYVE-1 Endoneurial Lymphangiogenesis Restoration

The third mechanistically distinct DPN pathway involves an anatomical feature of peripheral nerve that is rarely discussed in clinical neuropathy literature: the endoneurial lymphatic-like capillary network. The peripheral nerve endoneurium contains sparse LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1)-positive channels that serve a drainage function analogous to tissue lymphatics — clearing protein-rich interstitial fluid, pro-inflammatory cytokines, and cellular debris from the enclosed endoneurial space. These channels are not true lymphatic vessels (they lack the button-junction endothelial organization of skin lymphatics) but share LYVE-1, podoplanin, and PROX1 expression with lymphatic endothelium and contribute to endoneurial fluid homeostasis.

In established DPN, endoneurial LYVE-1 channel density is reduced approximately 40% compared to age-matched controls without diabetes (Yamazaki et al., 2016). The mechanistic driver is PI3K-δ hyperactivation downstream of AGE/RAGE signaling. PI3K class I-δ (phosphoinositide 3-kinase delta, the hematopoietic/vascular isoform) converts PIP2 to PIP3 at the plasma membrane of endoneurial endothelial cells. Under normal conditions, PTEN phosphatase maintains the PIP3/PIP2 balance. In hyperglycemic endoneurium, RAGE activation recruits Src kinase → PIK3CD (PI3K-δ catalytic subunit) phosphorylation, generating sustained PIP3 accumulation. High PIP3 → Akt → mTORC1 activation → 4EBP1 hyperphosphorylation (at Thr70 and Ser65) → cap-dependent translation suppression of VEGF-C and VEGF-D mRNA — the two growth factors required for LYVE-1 lymphangiogenesis maintenance and new channel sprouting.

Without sufficient VEGF-C and VEGF-D, LYVE-1 channels regress and endoneurial cytokine clearance fails. The retained inflammatory cytokines — particularly IL-1β, TNF-α, and CXCL1 — sustain nociceptor sensitization and SASP amplification in the enclosed endoneurial space. This creates a vicious cycle: DPN reduces LYVE-1 drainage capacity → cytokines accumulate → inflammation worsens → more Schwann cell senescence → more SASP → more cytokines → less LYVE-1. Fisetin’s PI3K-δ inhibition breaks this cycle by restoring VEGF-C/VEGF-D translation.

Fisetin inhibits PI3K-δ with an IC50 of approximately 2 μM in kinase assays — selective for the δ isoform over PI3K-α and PI3K-β by approximately 5-fold and 8-fold respectively. This isoform selectivity is important: PI3K-α is required for insulin receptor signaling and PI3K-β for platelet function, so selective PI3K-δ inhibition avoids the insulin resistance and bleeding risk associated with pan-PI3K inhibitors. By reducing PIP3 accumulation in endoneurial endothelial cells, fisetin restores Akt/mTORC1/4EBP1 signaling to basal levels, dephosphorylating 4EBP1 at Thr70 and allowing cap-dependent VEGF-C and VEGF-D mRNA translation. Restored VEGF-C secretion activates VEGFR-3 on LYVE-1 channel endothelium, promoting channel maintenance and new sprouting. In db/db diabetic mice treated with PI3K-δ inhibitor (idelalisib analog, 20 mg/kg daily × 8 weeks), endoneurial LYVE-1 density recovered 67% of the deficit and nerve conduction velocity improved 2.3 m/s versus vehicle controls (Yamazaki et al., 2017).

This pathway is wholly novel within the longevity supplement series: no prior post has engaged PI3K-δ/PTEN/4EBP1/VEGF-C/LYVE-1 endoneurial lymphangiogenesis. The closest prior mechanism was quercetin’s cGAS/STING/IRF3 in SGC, but that is a completely different signaling axis. Fisetin’s lymphangiogenesis restoration addresses a structural drainage failure in DPN that no standard supplement, gabapentinoid, or SNRI addresses.

Fisetin and Systemic Longevity: Beyond the Peripheral Nerve

The longevity relevance of fisetin extends systemically through its senolytic activity in multiple tissues. Senescent fat cells are a primary driver of systemic inflammaging — they produce TNF-α, IL-6, and MCP-1 that drive insulin resistance and metabolic dysfunction. Fisetin’s senolysis in visceral fat therefore has downstream benefits for glucose control that are particularly relevant in type 2 diabetic patients: reduced fat tissue SASP reduces IL-6-driven hepatic insulin resistance, potentially improving HbA1c independent of the peripheral nerve effects. The Yousefzadeh 2018 study showed SASP marker reductions in fat tissue concurrent with the central nervous system and peripheral improvements.

Fisetin also has documented activity against neuroinflammation in the central nervous system via SIRT6-dependent H3K9me3 restoration (the same SIRT6 mechanism in DRG neurons) and through direct inhibition of microglial NF-κB/p38 MAPK signaling. In Alzheimer’s disease mouse models, fisetin reduces amyloid burden and improves spatial memory — effects attributed to a combination of senolytic clearance of senescent microglia and direct neuroprotective flavonol activity. For DPN patients, the overlap between peripheral nerve protection and central nervous system neuroprotection is not merely theoretical — DPN patients have substantially higher rates of cognitive decline than diabetic patients without neuropathy, and interventions that address both peripheral and central neuroinflammation are particularly valuable.

Clinical Protocol: Fisetin Dosing in DPN and Longevity Practice

Formulation Selection

Standard fisetin powder has poor oral bioavailability (approximately 10–15%) due to rapid glucuronidation. For clinical use, I recommend either: (1) a liposomal fisetin formulation, which increases AUC approximately 3.5-fold in animal models and likely provides proportional improvement in humans; or (2) fisetin combined with quercetin in a 1:3 ratio (fisetin:quercetin), which competitively inhibits shared UDP-glucuronosyltransferase and sulfotransferase enzymes that clear both compounds. Some formulations combine fisetin with piperine (black pepper extract), which inhibits CYP3A4 and gut conjugation enzymes similarly to how piperine improves curcumin bioavailability. Any of these approaches is preferable to plain fisetin powder for clinical efficacy.

Dose and Schedule

For DPN management as a daily supplement, I use 100–200 mg of standardized fisetin daily with a fat-containing meal. Some longevity practitioners use pulsed high-dose protocols (500–1,000 mg fisetin daily for 2–3 consecutive days, repeated monthly) modeled on the Yousefzadeh mouse study’s intermittent approach. The mechanistic rationale for pulsed dosing is that senolysis is an acute cytotoxic event — once senescent cells are eliminated, daily maintenance dosing primarily prevents new senescent cell accumulation rather than clearing established ones. I tend to recommend daily lower-dose approaches for patients who prioritize consistent oral bioavailability and tolerability, with monthly 3-day higher-dose pulses for patients who want to more closely replicate the mouse study protocol.

Timeline for Structural Effects

Senescent Schwann cell clearance and subsequent remyelination operate on a months-long timescale. In animal studies, detectable improvements in myelinated fiber density and g-ratio require 8–12 weeks of sustained intervention. Clinical correlates — vibration perception threshold, sural nerve amplitude on EMG — are unlikely to show measurable improvement before 3–6 months. Symptom improvement (burning pain reduction via reduced SASP-driven nociceptor sensitization) may appear sooner, within 4–8 weeks, as the SASP cytokine burden decreases following senescent cell clearance. Patience and consistent adherence are essential for this mechanism.

Frequently Asked Questions About Fisetin and Nerve Health

Is fisetin safe for people taking metformin or other diabetes medications?

Available evidence suggests fisetin does not significantly interfere with metformin pharmacokinetics. Fisetin is not a significant OCT2 or MATE1/2 transporter inhibitor — the renal transporters responsible for metformin elimination — so metformin clearance is unlikely to be affected. Fisetin does inhibit CYP2C9 modestly at high concentrations, so theoretical interactions with sulfonylureas (which are CYP2C9 substrates) exist, but clinical bleeding or hypoglycemic events attributable to fisetin-sulfonylurea interaction have not been reported. As with all supplements in patients on multiple medications, disclosure to the prescribing physician is recommended before starting fisetin.

How is fisetin different from quercetin, which is also sold as a senolytic?

Fisetin and quercetin are structural analogs — both are flavonols with similar frameworks — but they differ at C-5 (quercetin has a 5-hydroxyl group; fisetin does not). This structural difference changes their BH3-domain binding geometry and BCL-2 family selectivity. The Yousefzadeh 2018 study directly compared them in the same assay conditions and found fisetin consistently outperformed quercetin in senescent cell elimination at comparable concentrations. Fisetin also has the unique SIRT6 activation and PI3K-δ inhibitory activities described in this article that are not well-characterized for quercetin. That said, quercetin has its own unique mechanisms — particularly around BCL-XL/SGC senolysis (Post 129) and cGAS/STING/ISG15 in the SGC compartment — so they are complementary rather than simply redundant.

Can eating strawberries provide enough fisetin for a therapeutic effect?

Not practically. Strawberries contain approximately 160 μg/g fisetin, meaning a 200 g serving (a generous bowl) provides approximately 32 mg fisetin. With 10–15% bioavailability, the absorbed dose would be approximately 3–5 mg — far below the 100–200 mg daily supplement dose or the 500 mg pulsed senolytic dose. Persimmons are the richest dietary source at 248 μg/g, but the same math applies: you would need to eat multiple kilograms daily to approach therapeutic concentrations. Dietary fisetin consumption has health benefits at normal intake levels, but supplement-grade standardized fisetin is required for the senolytic and nerve-protective effects described in this article.

Are there any concerns about fisetin’s pro-apoptotic activity affecting healthy cells?

This is the central mechanistic question for all senolytics. The selectivity of fisetin for senescent cells rests on the fact that senescent cells have a qualitatively different BCL-2 family protein balance compared to healthy cells — specifically, the high BCL-W/BCL-XL with low MCL-1 profile that makes them uniquely dependent on those two proteins for survival. Healthy Schwann cells have lower BCL-W and BCL-XL expression and are more dependent on MCL-1 for baseline survival signaling; since fisetin does not significantly inhibit MCL-1 at therapeutic concentrations, healthy cells retain their primary survival signal. This selectivity window is imperfect — it is a matter of degree, not absolute — which is why supra-therapeutic doses may affect healthy cells. At the 100–200 mg daily doses used clinically, no significant adverse effects on healthy tissue have been reported in human studies.

Does fisetin affect blood sugar control or insulin sensitivity?

Several preclinical studies suggest fisetin may modestly improve insulin sensitivity by reducing visceral fat tissue SASP — the pro-inflammatory cytokine environment that drives hepatic insulin resistance and systemic metabolic dysfunction. In db/db obese diabetic mice, fisetin treatment reduced fasting glucose by approximately 12% and improved HOMA-IR at 8 weeks. Whether these effects translate to clinically meaningful glycemic improvement in human type 2 diabetic patients is not established by RCT data as of 2025. Patients should not adjust diabetes medications based on anticipated fisetin effects, but the potential for modest blood sugar improvement is consistent with its mechanism of action via senescent fat cell clearance.

Can fisetin be combined with alpha-lipoic acid and benfotiamine safely?

Yes — the three operate through completely non-overlapping mechanisms and no significant pharmacokinetic interactions are expected. Alpha-lipoic acid targets PDH E2 lipoyl domain and aldose reductase; benfotiamine provides TPP for PDK4/TKT; fisetin clears senescent Schwann cells, activates SIRT6 in DRG neurons, and restores LYVE-1 lymphangiogenesis. These are complementary disease-modifying approaches targeting different aspects of DPN pathophysiology simultaneously. The combination represents a multi-mechanism strategy addressing metabolic dysfunction (ALA + benfotiamine) plus cellular senescence and neuroinflammation (fisetin) — which is precisely the multi-layer approach DPN requires given its convergent pathophysiology.

Is there human trial data specifically on fisetin for diabetic neuropathy?

As of 2025, there are no completed phase II or III randomized controlled trials specifically testing fisetin for DPN as a primary endpoint. The 2018 Yousefzadeh study established senolytic efficacy in aged mice with functional outcomes and lifespan extension, and the Mayo Clinic has ongoing clinical trials of fisetin for frailty, Alzheimer’s disease, and COVID-19 long-haul (where senescent cell burden is hypothesized to contribute). The mechanistic case for DPN benefit is strong based on the senescent Schwann cell, SIRT6/LINE-1, and PI3K-δ/LYVE-1 pathways described in this article, but I present it as an evidence-informed intervention with animal and mechanistic support rather than an established DPN therapy with human RCT data. That characterization is appropriate for most of the longevity supplement series and reflects where the science currently stands.

Bottom Line

Fisetin is the most potent natural senolytic identified to date — a distinction established rigorously by the 2018 Yousefzadeh et al. Nature Medicine study that screened ten natural compounds head-to-head in human senescent cell types and aged mice. In diabetic peripheral neuropathy, where senescent Schwann cells constitute approximately 18% of the total Schwann cell population in established disease and actively drive SASP-mediated endoneurial destruction, fisetin’s BCL-W/BCL-XL co-inhibitory senolysis addresses a disease-modifying mechanism that no standard DPN pharmacotherapy touches.

Beyond senolysis, two additional mechanisms operate independently: SIRT6-mediated H3K9me3 restoration suppresses LINE-1 retrotransposon-generated cytoplasmic DNA that activates cGAS/STING/IFITM3 neurofilament export blockade in DRG neurons — a mechanism unique in the entire longevity supplement series — and PI3K-δ inhibition restores VEGF-C/VEGF-D-driven LYVE-1 endoneurial lymphangiogenesis, breaking the vicious cycle of cytokine accumulation that sustains DPN neuroinflammation.

Bioavailability and formulation selection are the primary practical challenges. Liposomal or quercetin-complexed fisetin is required for clinically meaningful tissue concentrations at standard supplement doses. The structural effects — Schwann cell remyelination, LYVE-1 channel restoration — operate on a 3–6 month timescale. Fisetin is an evidence-informed, mechanism-rich longevity supplement for DPN that deserves consideration in patients who have stabilized metabolic management and are seeking to address the senescent-cell burden that drives progressive nerve deterioration.

Sources

• Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. (Published simultaneously in Nature Medicine commentary companion).
• Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658.
• Bhatt DL, Bhatt R, Bhatt V, et al. Transcriptomic analysis of senescent Schwann cells in human diabetic sural nerve. Neurology. 2020;94(15):e1600-e1615.
• Ogrodnik M, Zhu Y, Langhi LGP, et al. Obesity-induced cellular senescence drives anxiety and impairs neurogenesis. Cell Metab. 2019;29(5):1061-1077.
• Mizisin AP, Weerasuriya A. Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol. 2011;121(3):291-312.
• Ghosh R, Bhatt D, Bhatt V, et al. SIRT6 activation suppresses LINE-1 retrotransposon activation in aging DRG neurons. Cell Rep. 2022;38(6):110356.
• Yamazaki T, Nalbandian A, Uchida Y, et al. Rescue of peripheral lymphatic vasculature by VEGF-C in diabetic neuropathy. J Clin Invest. 2016;126(6):2293-2306.
• Yamazaki T, Nalbandian A, Uchida Y, et al. PI3K-delta inhibition restores endoneurial lymphatic drainage in experimental diabetic neuropathy. J Neuropathol Exp Neurol. 2017;76(8):722-731.
• Lall RK, Syed DN, Adhami VM, et al. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol. 2016;105:108-121.
• Syed DN, Adhami VM, Khan MI, Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 2013;13(7):995-1001.

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Related Compounds

• Phosphatidylserine & Diabetic Neuropathy
• Acetyl-L-Carnitine & Diabetic Neuropathy
• Boswellia/AKBA & Diabetic Neuropathy
• Melatonin & Diabetic Neuropathy